Skip to content

Edwards Lifesciences

US · EW #442 by market cap Listed 1970
101.85 -2.03 -1.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 6 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.2 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
91.57% -0.24pp
Institutions
1,666 -6
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund77.31%
Hedge Fund4.48%
Public Company3.51%
Government Pension Fund2.21%
Sovereign Wealth Fund1.55%
Private Company1.22%
Insurance Company0.36%
VC/PE Fund0.35%
Individual/Insider0.22%
Family Office/Trust0.22%
Other8.79%

Top holders as of 2026-09-30

BlackRock 10.22% · 58.75M sh
Vanguard Capital Management, LLC 7.13% · 40.97M sh
State Street Global Advisors 4.62% · 26.55M sh
Vanguard Portfolio Management, LLC 4.61% · 26.48M sh
J.P. Morgan Asset Management, Inc. 3.63% · 20.87M sh
Wellington Management Group 2.94% · 16.88M sh
Geode Capital Management, LLC 2.71% · 15.61M sh
Ninety One UK Limited 2.22% · 12.79M sh
Union Asset Management Holding AG 1.86% · 10.70M sh
BNY Mellon Asset Management 1.96% · 11.28M sh
Aristotle Capital Management, LLC 1.50% · 8.67M sh
Arrowstreet Capital, Limited Partnership 1.77% · 10.19M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 12 buys · 38 sells

NameRoleStake
Scott Ullem Former Corporate VP & CFO 0.05%
Larry Wood Former Corporate VP and Group President of TAVR & Surgical Structural Heart 0.03%
Donald Bobo Corporate Vice President of Strategy & Corporate Development 0.02%
Jean-Luc Lemercier Former Corporate Vice President of Japan, Asia Pacific & Greater China 0.03%
Bernard Zovighian Chief Executive Officer 0.02%
Steven Loranger Independent Director 0.01%
Kieran Gallahue Independent Director 0.01%
Nicholas Valeriani Independent Chairperson 0.01%
Leslie Heisz Independent Director 0.01%
Daveen Chopra Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies 0.00%
Ramona Sequeira Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Daniel Lippis Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Derivative Exercise and Sale -619 $72.68–104.25
2026-11-08 Donald Bobo Corporate Vice President of Strategy & Corporate Development Derivative Exercise and Sale -48,900 $72.68–103.05
2026-11-08 Bernard Zovighian Chief Executive Officer Derivative Exercise and Sale -23,100 $72.68–103.39
2026-10-07 Daniel Lippis Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Derivative Exercise and Sale -619 $72.68–85.65
2026-09-13 Wayne Markowitz GM & Senior VP of Surgical Structural Heart Sale to Issuer -923 $84.37–86.77
2026-09-12 Andrew Dahl Principal Accounting Officer, Senior VP & Corporate Controller Sale to Issuer -253 $84.37
2026-09-10 Daveen Chopra Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Sale to Issuer -398 $86.77
2026-09-10 Daniel Lippis Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Derivative Exercise and Sale -619 $72.68–87.51
2026-08-30 Andrew Dahl Principal Accounting Officer, Senior VP & Corporate Controller Open Market Disposition -544 $91.06
2026-08-27 Annette Bruls Corporate Vice President of EMEA, Canada, & Latin America Open Market Disposition -2,644 $89.98
2026-08-25 Daveen Chopra Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Derivative Exercise and Sale -31,800 $72.68–91.76
2026-08-25 Wayne Markowitz GM & Senior VP of Surgical Structural Heart Open Market Disposition -1,240 $91.47
2026-08-10 Daniel Lippis Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Derivative Exercise and Sale -619 $72.68–92.03
2026-07-29 Scott Ullem Former Corporate VP & CFO Intent to Sell (Form 144) -50,000 $92.50
2026-07-29 Wayne Markowitz GM & Senior VP of Surgical Structural Heart Open Market Disposition -146 $86.03
2026-07-27 Wayne Markowitz GM & Senior VP of Surgical Structural Heart Derivative Exercise and Sale -9,628 $74.02–85.06
2026-07-26 Bernard Zovighian Chief Executive Officer Other Acquisition +319 --
2026-07-26 Bernard Zovighian Chief Executive Officer Other Disposition -319 --
2026-07-26 Bernard Zovighian Chief Executive Officer Open Market Disposition -2,920 $83.93
2026-07-10 Annette Bruls Corporate Vice President of EMEA, Canada, & Latin America Sale to Issuer -109 $92.21

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Edwards Lifesciences discussion 0 comments

Add a comment